The Food and Drug Administration on Friday granted a fast-tracked approval for a new Alzheimer's disease treatment, which may slightly slow the progression of cognitive decline in the disease's early stages, but also raises risks of brain bleeds and swelling.The treatment-lecanemab, brand name Leqemb, made by pharmaceutical companies Eisai and Biogen-is an intravenous monoclonal antibody that targets amyloid-beta proteins, which accumulate in plaques in the brains of people with Alzheimer's.
#people #information #researchers #significantly #perspective #participants #dramatically #communications #clinical-trials #blood-clots
[
add
]
[
|
|
...
]